Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short

Merck and Daiichi pulled their bid for accelerated approval of I-DXd in small-cell lung cancer after FDA feedback. What patients should ask now.

Have A Referral?